Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health

被引:399
作者
Arif, S
Tree, TI
Astill, TP
Tremble, JM
Bishop, AJ
Dayan, CM
Roep, BO
Peakman, M
机构
[1] Univ London Kings Coll, Dept Immunobiol, Guys Kings & St Thomas Sch Med, London SE1 9RT, England
[2] Queen Elizabeth Hosp, Natl Hlth Serv Trust, London, England
[3] Univ Bristol, Royal Infirm, Dept Med, Bristol, Avon, England
[4] Leiden Univ, Ctr Med, Dept Immunohaematol & Blood Transfus, Leiden, Netherlands
关键词
D O I
10.1172/JCI200419585
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
According to the quality of response they mediate, autoreactive T cells recognizing islet beta cell peptides could represent both disease effectors in the development of type 1 diabetes (T1DM) and directors of tolerance in nondiabetic individuals or those undergoing preventative immunotherapy. A combination of the rarity of these cells, inadequate technology, and poorly defined epitopes, however, has hampered examination of this paradigm. We have identified a panel of naturally processed islet epitopes by direct elution from APCs bearing HLA-DR4. Employing these epitopes in a sensitive, novel cytokine enzyme-linked immunosorbent spot assay, we show that the quality of autoreactive T cells in patients with T1DM exhibits extreme polarization toward a proinflammatory Th1 phenotype. Furthermore, we demonstrate that rather than being unresponsive, the majority of nondiabetic, HLA-matched control subjects also manifest a response against islet peptides, but one that shows extreme T regulatory cell (Treg, IL-10-secreting) bias. We conclude that development of T1DM depends on the balance of autoreactive Th1 and Treg cells, which may be open to favorable manipulation by immune intervention.
引用
收藏
页码:451 / 463
页数:13
相关论文
共 37 条
[1]   T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes [J].
Almawi, WY ;
Tamim, H ;
Azar, ST .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (05) :1497-1502
[2]   Promiscuous binding of proinsulin peptides to Type 1 diabetes-permissive and -protective HLA class II molecules [J].
Astill, TP ;
Ellis, RJ ;
Arif, S ;
Tree, TIM ;
Peakman, M .
DIABETOLOGIA, 2003, 46 (04) :496-503
[3]  
Atkinson M, 2000, DIABETOLOGIA, V43, P819
[4]   Type 1 diabetes: new perspectives on disease pathogenesis and treatment [J].
Atkinson, MA ;
Eisenbarth, GS .
LANCET, 2001, 358 (9277) :221-229
[5]  
BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13
[6]   Diabetes antibody standardization program: First assay proficiency evaluation [J].
Bingley, PJ ;
Bonifacio, E ;
Mueller, PW .
DIABETES, 2003, 52 (05) :1128-1136
[7]   Optimized autoantibody-based risk assessment in family members - Implications for future intervention trials [J].
Bingley, PJ ;
Williams, AJK ;
Gale, EAM .
DIABETES CARE, 1999, 22 (11) :1796-1801
[8]   Suppressor T cells - they're back and critical for regulation of autoimmunity! [J].
Chatenoud, L ;
Salomon, B ;
Bluestone, JA .
IMMUNOLOGICAL REVIEWS, 2001, 182 :149-163
[9]   T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin [J].
Congia, M ;
Patel, S ;
Cope, AP ;
De Virgiliis, S ;
Sonderstrup, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3833-3838
[10]   Expression, purification and characterization of recombinant human proinsulin [J].
Cowley, DJ ;
Mackin, RB .
FEBS LETTERS, 1997, 402 (2-3) :124-130